semaglutide and cardiac risk A trial emulation in Nature Medicine shows that treatment with tirzepatide showed similar levels of benefit on cardiovascular outcomes in people at elevated cardiovascular with obesity and diabetes. Link nejm semaglutide cardiovascular GLP-1 receptor

Stress, poor sleep, hormonal imbalances, and the standard American diet can disrupt metabolic health at any age

What are the main differences between Wegovy and Trulicity

Effervescent Excellence: Our tablets dissolve quickly in water, ensuring efficient nutrient absorption

Its about whats happening inside my body. The Numbers Tell the Story Heres what the research shows us, and what I see clinically every day: 65.5% of women aged 40 to 59 have abdominal obesity 73.8% of women aged 60+ have abdominal obesity Women gain approximately 1.5 kg per year during perimenopause Average total weight gain during the menopause transition: 10 kg (22 lbs) Visceral fat can roughly double, from 5 to 8% to 10 to 15% of total body weight In my clinical experience, these numbers feel conservative

Each patients experience will be different, and the maintenance dose is decided based on how well the medication is working for them and whether they are experiencing any side effects, says Yusupov